1.Expert consensus on a stepwise strategy for the surgical management of empyema based on pathological staging (2026 edition)
Jichen QU ; Yunjiu GOU ; Guangyu CHEN ; Yongfu ZHAI ; Tinglong MA ; Xiaogang ZENG ; Feng JIN ; Yanzheng SONG ; Boxiong XIE ; Minjie MA ; Bin LI ; Jiang FAN
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2026;33(07):988-998
The surgical management of empyema (excluding those caused by mycobacterium tuberculosis and non-tuberculous mycobacteria) is rapidly evolving towards minimally invasive, precise, and stepwise approaches. The traditional three-stage classification (exudative, fibrinopurulent, and organizing) has limitations in guiding dynamic clinical decision-making. For the first time, this consensus explicitly identifies two critical junctures in the pathological progression of empyema: "early transformation" (stage Ⅰ to Ⅱ) and "late transformation" (stage Ⅱ to Ⅲ), and thereby constructs a corresponding "identification-early warning-intervention" stepwise therapeutic framework. The consensus emphasizes that proactive debridement via video-assisted thoracoscopic surgery should be performed during the early transformation phase to halt disease progression. Conversely, during the late transformation phase, therapeutic goals should be rationally adjusted to prioritize adequate drainage, avoiding futile pleural decortication. Moreover, the consensus underscores the pivotal role of precise perioperative etiological diagnosis (e.g. metagenomic nest-generation sequencing) and standardized anti-infective therapy. Integrating practical experiences from multiple thoracic surgery centers in China and relevant evidence-based literature, this consensus formulates recommendations on the precise definitions of staging, surgical indications for each phase, key technical points, perioperative management, and training systems. It aims to promote the standardized and individualized surgical management of empyema, ultimately optimizing patient prognosis.
2.Preoperative probing and dilation in nasolacrimal silicone intubation for incomplete primary acquired nasolacrimal duct obstruction
Cheng HU ; Yin LIU ; Jing CHEN ; Jinran FANG ; Nian XIANG ; Fan DU ; Bo ZENG
International Eye Science 2026;26(8):1316-1322
AIM:To assess the influence of preoperative lacrimal passage probing and dilation on the therapeutic effectiveness of nasolacrimal silicone intubation in cases of incomplete primary acquired nasolacrimal duct obstruction(PANDO).METHODS: A retrospective case-control clinical study was conducted. The study included patients with incomplete PANDO who underwent nasolacrimal silicone intubation at the hospital between October 2022 and October 2024. Participants were categorized into two groups based on their receipt of nasolacrimal duct probing and dilation prior to intubation. Group A consisted of patients who had undergone one or more sessions of nasolacrimal duct probing and dilation before nasolacrimal silicone intubation, while Group B included patients who did not receive nasolacrimal duct probing and dilation before intubation. All patients had their nasolacrimal silicone tubes removed 3 mo postoperatively and were monitored for 6 mo following tube removal to evaluate surgical success rates.RESULTS: A total of 136 patients(152 eyes)completed the six-month follow-up period. The overall surgical success rate for both groups was 72.4%(110/152 eyes).Group A included 22 males and 36 females, mean age 58.09±11.07 y, and achieved a success rate of 82.8%(53/64 eyes), while Group B included 27 males and 51 females, mean age 59.35±8.84 y and attained a success rate of 64.8%(57/88 eyes). The difference in surgical success rates between the two groups was statistically significant(P=0.014). Furthermore, Group A achieved a complete success rate of 67.2%(43/64 eyes), compared to 47.7%(42/88 eyes)in Group B, with this difference also reaching statistical significance(P=0.017). No serious postoperative complications were observed in either group.CONCLUSION: Nasolacrimal silicone intubation is a safe and effective intervention for incomplete PANDO, with preoperative nasolacrimal duct probing and dilation potentially enhancing therapeutic outcomes.
3.PADI1 promotes proliferation, migration, and invasion of clear cell renal cell carcinoma cells and its possible underlying mechanism
Li Tao1 ; Niu Yunfeng2 ; Wang Xingdan3 ; Zeng Kunpeng1 ; Chen Hao1 ; Hu Wenshi1 ; Fan Bo1
Chinese Journal of Cancer Biotherapy 2026;33(8):886-898
[摘 要] 目的:探讨肽基精氨酸脱亚胺酶1(PADI1)对肾透明细胞癌(ccRCC)细胞迁移、增殖、侵袭等生物学行为的影响及相关分子机制。方法:首先,利用转录组测序筛选肾癌组织与癌旁组织之间的差异表达基因,并通过GEPIA、TIMER2.0等数据库分析其差异表达水平。选取2024至2025年河北医科大学第四医院泌尿外科术中留存的59例ccRCC患者的组织标本,用RT-qPCR法、免疫组化SP法检测肾癌组织及癌旁组织中PADI1的表达水平,分析其与各临床参数之间的关系。通过划痕愈合、CCK-8、克隆形成及Transwell实验评估PADI1对ccRCC细胞迁移、增殖和侵袭能力的影响,用流式细胞术检测PADI1对细胞周期的影响,并采用WB法检测A498细胞转染si-PADI1后角质化包膜(CE)形成通路及EMT相关蛋白表达的变化。结果:在ccRCC组织中PADI1的相对表达量显著高于癌旁正常组织(P < 0.01),并与患者年龄、淋巴结转移、远处转移及临床分期相关(P < 0.05)。A498和ACHN细胞中转染si-PADI1,可以有效地下调PADI1 mRNA和蛋白表达水平(P < 0.05);而转染过表达质粒则能够显著上调其表达(P < 0.05),敲低PADI1能够显著抑制其迁移(P < 0.05)、增殖(P < 0.05)与侵袭能力(P < 0.001),而过表达则增强其迁移(P < 0.05)、增殖(P < 0.05)与侵袭能力(P < 0.001),但对细胞周期影响不显著。在A498细胞中,WB实验结果显示PADI1表达能够改变EMT及CE通路相关蛋白表达水平。结论:PADI1在ccRCC中高表达且与ccRCC患者年龄及其淋巴结转移、远处转移、临床分期有关联,其表达水平升高能够影响CE形成通路及加速EMT进程,并增强ccRCC细胞的迁移、增殖、侵袭能力。
4.Establishment and evaluation of an integrated central pharmacy management model
Xing CHANG ; Qi ZENG ; Yinwei FAN ; Jingjing MA ; Jian’an BAO ; Danyan SHAO
China Pharmacy 2026;37(18):2437-2441
OBJECTIVE To establish an integrated central pharmacy management model combining the inpatient pharmacy and the pharmacy intravenous admixture service (PIVAS), and to evaluate its effectiveness and economic value in terms of operational cost composition, dispensing output, and dispensing efficiency.METHODS Through spatial integration, flexible staff scheduling, the application of intelligent equipment, and a dual prescription review system, the inpatient pharmacy and PIVAS were integrated, and an integrated management model was implemented. Operational data from the Fourth Affiliated Hospital of Soochow University (hereinafter referred to as “our hospital”) in 2023 were selected for analysis, with national median data and data from another hospital in the same region that still implemented a separate management model for the inpatient pharmacy and PIVAS serving as controls. The activity-based costing method was used to calculate operating costs. Dispensing output, dispensing efficiency, and unit activity cost were compared among the three. Cost-benefit analysis was further conducted by calculating the net benefit (NB) and the incremental cost-effectiveness ratio (ICER) for economic evaluation.RESULTS Under the integrated central management model, the total operational cost of our hospital’s central pharmacy was 3.968 3 million yuan, representing an 11.80% reduction compared with the external hospital’s pharmacy (4.499 0 million yuan), with consumable costs and labor costs decreasing by 38.73% and 10.99%, respectively. The total prescription dispensing volume (3.613 4 million orders) was 43.58% higher than that of the external hospital’s pharmacy (2.516 7 million orders). The daily dispensing volume per capita reached 471.41 medication orders, 3.5 times that of the external hospital’s pharmacy (135.20 medication orders). The unit activity cost was 1.10 yuan, showing a 38.55% decrease relative to the external hospital’s pharmacy (1.79 yuan). The NB was 755 200 yuan, and the ICER was -2.36. In terms of PIVAS operations, the daily dispensing volume per capita for general infusions (including antibacterial drugs) in our hospital was 50.83 sets, higher than the national PIVAS median (49.11 sets) and the external hospital pharmacy (36.14 sets); the daily dispensing volume per capita for hazardous drugs was 0.86 sets, higher than the national median (0.70 sets) and the external hospital pharmacy (0.16 sets).CONCLUSIONS The integrated central pharmacy management model established by our hospital achieved reduced operational costs and enhanced staff efficiency despite growing service volumes. Integrating the functions of both the inpatient pharmacy and the PIVAS, this model outperformed national medians and peer hospitals in dispensing output, dispensing efficiency, unit activity cost control, and economic evaluation, and surpassed the national median specifically in PIVAS dispensing efficiency.
5.Donation-related adverse reactions and individual voluntary donation behavior following adjustments of the upper age limit for blood donation: a multicenter retrospective cohort study
Chenying WANG ; Jue WANG ; Changping LI ; Wei CHEN ; Ying LI ; Dan BAO ; Yuanqin ZHANG ; Xin ZHAO ; Jinfeng ZENG ; Yuwei HU ; Shuchang DAI ; Xiaoqiang WU ; Weimin FAN
Chinese Journal of Blood Transfusion 2026;39(9):1168-1178
Objective: To evaluate the risk of donation-related adverse reactions, donation behavior, and contributions to the blood supply among donors aged 56-65 years following extension of the upper age limit for voluntary blood donation, and to provide real-world evidence for optimizing blood donation age policies in China. Methods: A multicenter retrospective cohort was established using blood donation databases from Hainan, Shenzhen, and Jiangxi. A total of 1 180 767 donors contributing 2 020 407 whole-blood and apheresis donations were included. Donations were classified by donor age at each donation into the 18-55-year and 56-65-year groups. Generalized estimating equation (GEE) models were used to compare the risks of overall, local, and systemic donation-related adverse reactions between the two age groups. Restricted cubic spline analysis was used to assess the continuous association between donor age and the risk of overall adverse reactions. Poisson GEE models were used to compare annual donation frequency, and donation participation and contributions to the blood supply among donors aged 56-65 years were evaluated. The study was approved by the Ethics Committee of the Institute of Blood Transfusion, Chinese Academy of Medical Sciences (No.2025012) and registered with the Chinese Clinical Trial Registry (ChiCTR2500114960). Results: A total of 1 960 711 donations were included in the 18-55-year group and 59 696 in the 56-65-year group. The overall donation-related adverse reaction rates were 3.890‰and 0.704‰, respectively. Multivariable GEE analysis showed that, compared with donors aged 18-55 years, those aged 56-65 years had lower risks of overall adverse reactions (adjusted OR=0.294, 95%CI: 0.217-0.398, P<0.001) and systemic adverse reactions (adjusted OR=0.163, 95%CI: 0.101-0.263, P<0.001), whereas no statistically significant difference was observed in the risk of local adverse reactions (adjusted OR=1.337, 95%CI: 0.487-3.670, P=0.573). Donor age was nonlinearly associated with the risk of overall adverse reactions (P overall<0.001, P nonlinear<0.001), with the risk generally decreasing with increasing age between 18 and 65 years. The mean annual donation frequency was higher among donors aged 56-65 years than among those aged 18-55 years (1.63 vs 1.24 donations per year; adjusted IRR=1.34, 95%CI: 1.30-1.39, P<0.001). During the study period, donors aged 56-65 years contributed 2.95% of all donations; their whole-blood donations and whole-blood collection volume accounted for 2.36% and 2.37% of the corresponding totals, respectively. Conclusion: Under current health screening and standardized donor management, donors aged 56-65 years did not show an increased risk of short-term donation-related adverse reactions and demonstrated a higher annual donation frequency, together with a measurable contribution to the blood supply. These findings support appropriately extending the upper age limit for voluntary blood donation under strict health screening to broaden the donor pool and supplement the blood supply.
6.Potential confusion risk screening and display-name optimization for Chinese drug names based on a multimodal similarity model
Feng WANG ; Qi WANG ; Yuanyuan FAN ; Panke ZENG ; Haiyan DONG
China Pharmacy 2026;37(19):2570-2576
OBJECTIVE To construct a multimodal similarity model for Chinese drug names and design optimized display names,compare the potential confusion risk of display names of the same drug catalogue in different scenarios,so as to provide a quantitative basis for the management of drug display names.METHODS A total of 1 221 drug entries were extracted from the drug dictionary of a tertiary grade A hospital,forming 744 810 drug pairs. “Five rules” were summarized based on the confusion characteristics of candidate confusable drug pairs under the currently used in-hospital display names (Scenario 1) and standard display names (Scenario 2),to generate optimized display names (Scenario 3). A multimodal similarity model integrating Pinyin,glyph,character sequence and rendered visual features was constructed. The same threshold (total similarity S total ≥0.70) was adopted to screen candidate confusable drug pairs. Confusion risk grading and transition,confusion characteristic labeling,confusion network clustering and residual cluster analysis were carried out. The naming mechanism of optimized display names was investigated through display morphology indicators and rule ablation,and the robustness of the comparison results among the three scenarios was evaluated through similarity threshold and fusion weight sensitivity analysis.RESULTS The numbers of candidate confusable drug pairs in the three scenarios were 156,269 and 83 respectively,among which the number of pairs at high risk and above was 109, 215 and 64 respectively. Compared with Scenario 1,Scenario 3 reduced the number of candidate confusable drug pairs by 46.8%,and the number of those at high risk or above decreased by 41.3%. Display morphology analysis showed that Scenario 3 had the lowest average ink density (0.057 3) and the largest average number of structural slots (2.99). Rule ablation analysis showed that after disabling the rule of manufacturer characteristic abbreviation prompts,the number of candidate confusable drug pairs increased the most (+74 pairs),while disabling structured naming alone resulted in a net decrease of 9 pairs. The residual clusters mainly involved drugs with the same active ingredient but different specifications or subtypes,as well as series products from the same manufacturer with similar main name stems. Under the threshold setting of 0.60 to 0.80 with a step size of 0.025 and 11 different weight configurations (including the baseline value),the number of candidate confusable drug pairs always maintained the ranking of Scenario 3<Scenario 1<Scenario 2.CONCLUSIONS The multimodal similarity model can be used for quantitative screening of potential confusion of Chinese drug display names,and the ranking of the number of candidate confusable drug pairs among scenarios remains stable within the set parameter range. The optimized display names based on the “five rules” can reduce the number of candidate confusable drug pairs, and the number of those at high risk or above in the hospital’s drug catalogue,but their impact on actual identification behavior and clinical medication safety still needs further verification.
7.Systematic review and Meta-analysis of factors influencing taste alterations in cancer patients undergoing chemotherapy
Jing LI ; Qiuting MAO ; Yi HUANG ; Fan ZENG ; Mo XIONG ; Qianqian LI ; Shuanghong ZHOU
Chinese Journal of Nursing 2025;60(14):1778-1785
Objective To systematically evaluate the factors affecting taste alteration in patients undergoing cancer chemotherapy.Methods PubMed,Cochrane Library,Web of Science,CINAHL,Embase,CBM,CNKI,WanFang Data and VIP were searched from the establishment until August 1,2024.The retrieved literature was independently screened,evaluated and the data were extracted by 2 researchers,and statistical analysis was performed using Stata 17.0 software.Results A total of 18 studies were included,involving 4 686 patients.The incidence of taste changes is 73.46%.Totally 9 influencing factors were extracted through quantitative analysis,including oral mucositis(OR=1.98),dry mouth(OR=1.82),nausea(OR=3.05),loss of appetite(OR=2.41),use of triple antiemetic drugs(OR=2.45),gynecological cancers(OR=0.67),lung cancer(OR=0.57),paclitaxel types of chemotherapy d rugs(OR=2.86),and smoking(β=9.38).Conclusion The alteration of taste in cancer chemotherapy patients is in-fluenced by multiple factors.Nurses should regularly and dynamically assess changes in taste and implement individualized and refined nursing interventions in clinical practice to prevent or delay the development of taste alterations,thereby improving patients' quality of life and treatment adherence.
8.Evaluation of the effect of graded exercise rehabilitation on patients with acute exacerbation of chronic obstructive pulmonary disease
Nana YANG ; Chuanli CHENG ; Hui ZENG ; Dandan FU ; Yan WANG ; Yue CHEN ; Hongmin RAN ; Hongjing FAN ; Xia LONG
Chinese Journal of Nursing 2025;60(9):1062-1068
Objective To analyze the effect of graded exercise rehabilitation in patients with acute exacerbation of chronic obstructive pulmonary disease,and to provide references for clinical nursing practice.Methods A total of 70 patients with acute exacerbation of chronic obstructive pulmonary disease who met the criteria in the Department of Respiratory Medicine of a tertiary hospital in Zunyi City from September to December 2023 were randomly divided into an experimental group and a control group(with 35 cases in each group).The experimental group implemented graded exercise rehabilitation based on the Global Chronic Obstructive Pulmonary Initiative guidelines,and the control group implemented routine exercise rehabilitation.After intervention,the lung function,blood gas analysis,oxygenation index,6 min walking test and the incidence of complications related to non-invasive mechanical ventilation were compared between the 2 groups.Results Finally,34 cases were included in the experimental group and 35 cases in the control group.After intervention,the forced expiratory volume in the first second of the experimental group was improved compared with the control group(P<0.05).The 6-minute walking test of the experimental group was higher than that of the control group(P<0.05).The total incidence of non-invasive mechanical ventilation-related complications in the experimental group was lower than that in the control group(P<0.05).There was no significant difference in blood gas analysis and oxygenation index between the 2 groups(P<0.05).Conclusion The implementation of graded exercise rehabilitation based on the Global Chronic Obstructive Pulmonary Initiative guidelines can help patients with acute exacerbation of chronic obstructive pulmonary disease improve their respiratory function,improve their exercise endurance,and reduce non-invasive mechanical ventilation-related complications.
9.Diagnosis and treatment guideline for acute cervical spinal cord injury without fracture-dislocation in adults (version 2025)
Qingde WANG ; Tongwei CHU ; Jian DONG ; Liangjie DU ; Haoyu FENG ; Shunwu FAN ; Shiqing FENG ; Yanzheng GAO ; Yong HAI ; Da HE ; Dianming JIANG ; Jianyuan JIANG ; Bin LIN ; Bin LIU ; Baoge LIU ; Fang LI ; Feng LI ; Li LI ; Weishi LI ; Fangcai LI ; Xiaoguang LIU ; Hongjian LIU ; Yong LIU ; Zhongjun LIU ; Shibao LU ; Xuhua LU ; Keya MAO ; Xuexiao MA ; Yong QIU ; Limin RONG ; Jun SHU ; Yueming SONG ; Tiansheng SUN ; Yan WANG ; Zhe WANG ; Zheng WANG ; Bing WANG ; Linfeng WANG ; Yu WANG ; Qinghe WANG ; Jigong WU ; Hong XIA ; Guoyong YIN ; Jinglong YAN ; Wen YUAN ; Yong YANG ; Qiang YANG ; Cao YANG ; Jie ZHAO ; Jianguo ZHANG ; Yue ZHU ; Zezhang ZHU ; Yingjie ZHOU ; Zhongmin ZHANG ; Yan ZENG ; Dingjun HAO ; Baorong HE ; Wei MEI
Chinese Journal of Trauma 2025;41(3):243-252
Cervical spinal cord injury without fracture-dislocation (CSCIWFD) is referred to as a special type of cervical spinal cord injury characterized by traumatic spinal cord dysfunction and no significant bony structural abnormalities on imagines. Duo to the high risk of missed diagnosis during the initial consultation, CSCIWFD may lead to progressive neurological deterioration or even complete paralysis, severely impacting patients′ prognosis. Currently, there are no established consensuses over the diagnosis and treatment of CSCIWFD, such as the lack of evidence-based standards for indications of non-surgical treatment and risk of secondary neurological injury, as well as debates over the optimal timing for surgical intervention and indications for different surgical approaches. To address these issues, the Spine Trauma Group of the Orthopedic Branch of the Chinese Medical Doctor Association organized experts in the relevant fields to formulate Diagnosis and treatment guideline for acute cervical spinal cord injury without fracture- dislocation in adults ( version 2025) . Based on evidence-based medicine and the principles of scientific rigor and clinical applicability, the guidelines proposed 11 recommendations covering terminology, diagnosis, evaluation treatment, and rehabilitation, etc., aiming to standardize the management of CSCIWFD.
10.Guideline for the prevention of intraoperative acquired pressure injury in paraplegic patients with spinal cord injury (version 2025)
Aijun XU ; Shuixia LI ; Bo CHEN ; Mengyuan YE ; Lejiao LANG ; Ning NING ; Lin ZHANG ; Changqing LIU ; Zhonglan CHEN ; Weihu MA ; Weishi LI ; Xiaoning WANG ; Dongmei BIAN ; Jiancheng ZENG ; Xin WANG ; Yuan GAO ; Yaping CHEN ; Jiali CHEN ; Yun HAN ; Xiuting LI ; Yang ZHOU ; Xiaojing SU ; Qiong ZHANG ; Tianwen HUANG ; Ping ZHANG ; Hua LIN ; Xingling XIAO ; Ruifeng XU ; Fanghui DONG ; Bing HAN ; Luo FAN ; Yanling PEI ; Suyun LI ; Xiaoju TAN ; Rongchen GUO ; Yefang ZOU ; Xiaoyun HAN ; Junqin DING ; Yi WANG ; Shuhua DENG ; Jinli GUO ; Yinhua LIANG ; Yuan CEN ; Xiaoqin LIU ; Junru CHEN ; Haiyang YU ; Lunlan LI ; Ying REN ; Yunxia LI ; Jianli LU ; Ying YING ; Lan WEI ; Yin WANG ; Qinhong XU ; Yanqin ZHANG ; Yang LYU ; Shijun ZHANG ; Sui WENJIE ; Sanlian HU ; Shuhong YANG ; Guoqing LI ; Jingjing AN ; Baorong HE ; Leling FENG
Chinese Journal of Trauma 2025;41(6):530-541
Paraplegia caused by spinal cord injury is a serious neurological complication, for which surgery is currently the main treatment method. Due to different surgical approaches, patients are usually expected to maintain a passive prone position for a long time or switch between the supine and prone positions. Affected by multiple factors such as neurogenic sensory disorders, pathological changes in muscle tone and operative duration, the risk of intraoperative acquired pressure injury (IAPI) is significantly increased. Current clinical prevention strategies for IAPI in these patients predominantly focus on localized pressure relief during positioning, lacking systematic, standardized comprehensive prevention protocols or evidence-based guidelines. To address it, Department of Nursing, Orthopedics Branch, China International Exchange and Promotive Association for Medical and Health Care, Spinal Trauma Professional Committee, Orthopedics Branch, Chinese Medical Doctor Association, Nursing Group of Spine and Spinal Cord Professional Committee of Chinese Association of Rehabilitation Medicine organized experts in relevant fields to formulate Guideline for the prevention of intraoperative acquired pressure injury in paraplegic patients with spinal cord injury ( version 2025), based on evidence-based medical evidence and latest research results and clinical practice at home and abroad. Eleven recommendations were put forward from the aspects of preoperative risk assessment, intraoperative prevention strategies, postoperative handover and monitoring, and supportive mechanisms for IAPI prevention, aiming to standardize the prevention measures and management strategies of IAPI in paraplegic patients with spinal cord injury and accelerate the recovery of patients and improve the therapeutic effect.

Result Analysis
Print
Save
E-mail